Pundole Xerxes, Suarez-Almazor Maria E
Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Unit 1444, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Unit 1444, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rheum Dis Clin North Am. 2020 Aug;46(3):445-462. doi: 10.1016/j.rdc.2020.05.003. Epub 2020 Jun 7.
Management of rheumatoid arthritis (RA) in patients with cancer is complex and requires a multidisciplinary approach. A few studies have examined the risk for recurrence in patients with RA receiving disease-modifying antirheumatic drugs, primarily tumor necrosis factor-α inhibitors. Although these agents seem to be safe in patients with a history of cancer and no evidence of disease, additional information is needed to determine their potential effects in patients with RA and active cancer. Patients with RA undergoing cancer therapy, including surgery, radiation, chemotherapy, and immunotherapy, need to be carefully monitored because they are at increased risk for adverse events.
癌症患者类风湿关节炎（RA）的管理很复杂，需要多学科方法。一些研究探讨了接受改善病情抗风湿药物（主要是肿瘤坏死因子-α抑制剂）的RA患者的复发风险。尽管这些药物在有癌症病史且无疾病证据的患者中似乎是安全的，但仍需要更多信息来确定它们对患有RA和活动性癌症患者的潜在影响。正在接受癌症治疗（包括手术、放疗、化疗和免疫治疗）的RA患者需要仔细监测，因为他们发生不良事件的风险增加。
